6CM
ATNM icon

683 Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

683 Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,000
Closed -$151K – 178
2023
Q1 		$151K Sell
16,000
-629
-4% -$6.64K 0.01% 202
2022
Q4 		$177K Buy
+16,629
New +$169K 0.02% 195

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

683 Capital Management's ATNM Position: Q2 2023 in Review

683 Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2023, closing a stake of 16,000 shares — an estimated $151K sold.

683 Capital Management first reported a position in ATNM in Q4 2022 and held it in 2 quarters. The position peaked at $177K in Q4 2022. 71 funds tracked by Wall St. Rank hold ATNM as of Q2 2023.

  • 683 Capital Management reported no remaining Actinium Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 16,000 Actinium Pharmaceuticals shares in Q2 2023, an estimated $151K.
  • 683 Capital Management first reported a position in Actinium Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Actinium Pharmaceuticals position peaked at $177K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.